^
Association details:
| Biomarker: | MYCN amplification |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
Excerpt:
...nor crizotinib was able to inhibit growth of the non-ALK addicted neuroblastoma cell lines, IMR32 and CLB-PE, indicating that…nor crizotinib inhibitor was toxic to cells at the levels employed...
DOI:
10.18632/oncotarget.8510
